| Dr Robert John Bierwirth, MD | |
|
1150 Reservoir Ave, Suite 201, Cranston, RI 02920-6068 | |
| (401) 943-1300 | |
| Not Available |
| Full Name | Dr Robert John Bierwirth |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 21 Years |
| Location | 1150 Reservoir Ave, Cranston, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053517565 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 13848 (Rhode Island) | Primary |
| 207RI0008X | Internal Medicine - Hepatology | 13848 (Rhode Island) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| South County Hospital Inc | Wakefield, RI | Hospital |
| Roger Williams Medical Center | Providence, RI | Hospital |
| Our Lady Of Fatima Hospital | North providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Internal Medicine Associates Inc | 9234029257 | 10 |
News Archive
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.
Senomyx, Inc., a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Firmenich SA, the world's largest privately-owned fragrance and flavor company, has made a decision to proceed with commercial development of S6973, Senomyx's enhancer of sucrose (table sugar) that has demonstrated the ability to reduce up to 50% of the sugar in a variety of products while maintaining the taste of natural sugar.
Attacks against health care workers, health facilities and people in need of medical care during armed conflict and other situations of violence pose one of the major humanitarian challenges in the world today and must end. This was the message delivered today, 12 August 2011, at the Australian launch of the global International Red Cross and Red Crescent Health Care in Danger project in Sydney.
The diabetes drug sitagliptin appears to reduce the severity of reactive hypoglycemia, a form of low blood sugar that occurs after a meal, a preliminary study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.
› Verified 9 days ago
| Entity Name | Internal Medicine Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376553990 PECOS PAC ID: 9234029257 Enrollment ID: O20040316000141 |
News Archive
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.
Senomyx, Inc., a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Firmenich SA, the world's largest privately-owned fragrance and flavor company, has made a decision to proceed with commercial development of S6973, Senomyx's enhancer of sucrose (table sugar) that has demonstrated the ability to reduce up to 50% of the sugar in a variety of products while maintaining the taste of natural sugar.
Attacks against health care workers, health facilities and people in need of medical care during armed conflict and other situations of violence pose one of the major humanitarian challenges in the world today and must end. This was the message delivered today, 12 August 2011, at the Australian launch of the global International Red Cross and Red Crescent Health Care in Danger project in Sydney.
The diabetes drug sitagliptin appears to reduce the severity of reactive hypoglycemia, a form of low blood sugar that occurs after a meal, a preliminary study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert John Bierwirth, MD 1150 Reservoir Ave, Suite 201, Cranston, RI 02920-6068 Ph: (401) 943-1300 | Dr Robert John Bierwirth, MD 1150 Reservoir Ave, Suite 201, Cranston, RI 02920-6068 Ph: (401) 943-1300 |
News Archive
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.
Senomyx, Inc., a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Firmenich SA, the world's largest privately-owned fragrance and flavor company, has made a decision to proceed with commercial development of S6973, Senomyx's enhancer of sucrose (table sugar) that has demonstrated the ability to reduce up to 50% of the sugar in a variety of products while maintaining the taste of natural sugar.
Attacks against health care workers, health facilities and people in need of medical care during armed conflict and other situations of violence pose one of the major humanitarian challenges in the world today and must end. This was the message delivered today, 12 August 2011, at the Australian launch of the global International Red Cross and Red Crescent Health Care in Danger project in Sydney.
The diabetes drug sitagliptin appears to reduce the severity of reactive hypoglycemia, a form of low blood sugar that occurs after a meal, a preliminary study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.
› Verified 9 days ago
Susan H Hart, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1052 Park Ave, Cranston, RI 02910 Phone: 401-275-5039 | |
Thomas Henry Mcgreen, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1150 Reservoir Ave, Suite 201, Cranston, RI 02920 Phone: 401-943-1300 Fax: 401-946-8480 | |
Dr. Gregory G Allen, D.O. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1681 Cranston St, Suite D, Cranston, RI 02920 Phone: 401-946-8446 Fax: 401-946-8340 | |
Dr. Robert L Graves, D.O. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1150 Reservoir Ave, Suite 304, Cranston, RI 02920 Phone: 401-942-3330 Fax: 401-942-3833 | |
Dr. Steven Michael Sepe, M.D., PH.D Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 25 Belle Isle Way, Cranston, RI 02921 Phone: 401-942-7843 Fax: 401-942-7843 | |
Ms. Jun O Parks, M. D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 333 Budlong Rd, Cranston, RI 02920 Phone: 401-943-4530 |